2KKaya MG, Yalcin R, Okyay K, et al. Potential role of plasma my- eIoperoxidase level in predicting long-term outcome of acute myo- cardial infarction[ J1. Tex Heart Inst J, 2012,39(4) :500-506.
3Monaco C, Paleolog E. Nuclear factor kappaB : a potential therapeu- tic target in atherosclerosis and thrombosis [J]. Cardiovasc Res, 2004,61(4) :671- 682.
4Jneid H. The 2012 ACCF/AHA focused update of the unstable angi- na/non-ST-elevation myocardial iniarction ( UA/NSTE-MI ) guide- line: a critical appraisal [ J]. Methodist Debakey Cardiovasc J, 2012,8(3 ) :26-30.
5Yayan J. Emerging families of biomarkers for coronary artery dis- ease: inflammatory mediators [ J ]. Vasc Health Risk Manag, 2013, (9) :435-456.
6Koenig W. High-sensitlvity C-reactive protein and atherosclerotic disease: from improved riskprediction to risk-guided therapy[ J ]. Int J Cardiol, 2013,7(13) : 1324-1327.
7Lrpez A, Manzano S, Lip GY, et al. Interleukin-6 and high-sensi- tivity C-reactive protein for the prediction of outcomes in non-ST- segment elevation acute coronary syndromes[ J]. Rev Esp Cardiol, 2013,66(3) :185-192.
8Hong YJ, Jeong MH, Choi YH, et al. Relation between high-sen- sitivity C-reactive protein and coronary plaque components in pa- tients with acute coronary syndrome: virtual histology-intravascular ultrasound analysis [ J ]. Korean Circ J, 2011,41 ( 8 ) :440 -446.
9Anatoliotakis N, Deftereos S, Bouras G. et al. Myeloperoxidase: expressing inflammation and oxidative stress in cardiovascular dis- ease[J]. Curt Top Med Chem, 2013,13(2):115-138.
10Gran6r M, Tikkanen E, Rimpila O, et al. Diagnostic efficacy of myeloperoxidase to identify acute coronary syndrome in subjects with chest pain[J]. Ann Med, 2013,45(4) :322-327.
